



## Yu Lu, PhD

Partner | Boston | 617.449.6523  
ylu@mccarter.com

Intellectual Property | Patents | Life Sciences | Healthcare

Louie's deep technical background is the foundation of his patent strategies for biotechnology and pharmaceutical clients.

Dr. Yu "Louie" Lu focuses his practice on strategic patent portfolio development and management for biotechnology, pharmaceutical, and medical device companies, as well as leading academic institutions. Louie has extensive experience in preparing and prosecuting U.S. and foreign patent applications in fields including chemistry, renewable energy, genetics, cell biology, immunology, RNA interference, drug delivery, stem cell, pharmaceuticals, and medical device.

Louie also advises clients on matters relating to technology transfer and licensing, product clearance including patent landscape analysis and freedom-to-operate, non-infringement and/or invalidity opinions, patentability analysis, and due diligence investigations.

Prior to starting his legal career at a global law firm as a patent agent and then a patent attorney, Louie was a Jane Coffin Childs Postdoctoral Fellow at the Department of Cell Biology, Harvard Medical School, after completing his PhD training in the Cell & Developmental Biology Program at Harvard University in 1999. Louie's research has led to the publication of multiple scientific articles in journals such as *Genes & Development*, *Nature Medicine*, *Proc. Natl. Acad. Sci.*, *Mol. Cell. Biol.*, and *Oncogene*. He received his BSc in Genetics and Genetic Engineering from Fudan University (Shanghai, China), and graduated No. 1 in his undergraduate class. Louie was awarded the Excellent Undergraduate Student Award by the Shanghai Municipal Government in 1990.

### Representative Matters

#### Biotechnology start-up—Patent prosecution

Drafted and prosecuted a ground-breaking small molecule cancer drug developed by a biotechnology start-up company, leading to the acquisition of the patent portfolio by a multi-national pharmaceutical company, and continued representation of the multi-national pharmaceutical company in follow-up patent prosecution to cover intellectual property arising from clinical trials of the small molecule drug.

#### Large pharmaceutical company—Patent prosecution

Managed world-wide prosecution of a patent portfolio for a large pharmaceutical company and secured patents covering a small molecule drug that recently received FDA approval.

#### China-based pharmaceutical company—Company formation and patent portfolio development

Led strategic planning and execution of company formation, followed by patent portfolio development and management, for a China-based pharmaceutical company with US presence, and continued to advise the client for clinical trial.

**Biotechnology start-up—Patent prosecution strategy**

Developed global patent prosecution strategy for a biotechnology start-up company that has developed a novel class of related small molecule cancer drugs, and assisted IP licensing negotiation with a large pharmaceutical company to out-license a portion of the patent portfolio.

**International clients—Advice on US-specific issues**

Routinely advises international clients from Europe and Asia about US-specific issues such as on sale bar, patent term adjustment, double patenting, and patent term extension under the Hatch-Waxman Act.

---

**Education**

Boston College Law School, JD, *cum laude*, 2006

Harvard University, PhD Cell and Molecular Biology, 1999

Fudan University, China, BSC Genetics and Genetic Engineering, with highest honors, 1990

**Bar Admissions**

Massachusetts

U.S. Patent & Trademark Office

**Memberships and Certifications**

Boston Patent Law Association

**Languages**

Mandarin

**Recognitions\***

*The Best Lawyers in America*, Patent Law, Massachusetts, 2024

\* No aspect of this or any advertisement has been approved by the Supreme Court of New Jersey. For ranking methodologies, please see [here](#).

## **Speaking Engagements**

Patents & Trademarks & Copyrights (Oh My!): Protecting Your Startup's Most Valuable Assets, McCarter & English Entrepreneurs Series, 10.1.2014